- 6 次围观
产品图片
产品别名
货号/SKU
EMN002-FP
货号/规格
1 vial
库存与交货期
4-6 周
人民币价格
14050
试剂海关审批
使用人负责A/B风险申请资质
国外采购
支持/部分需签MTA
厂牌
Kerafast, Inc.
品牌
产品基础信息
From the laboratory of Jaime F. Modiano, VMD, PhD, University Minnesota, Twin Cities.
产品描述信息
Product Type: | Cell Line |
Name: | OSCA-32 |
Cell Type: | Osteosarcoma |
Organism: | Dog |
Morphology: | Spindle |
Source: | Bone (radius) |
Biosafety Level: | 2 |
Growth Conditions: | DMEM, 10mM HEPES, 10% FBS, 100ug/mL Primocin |
Subculturing: | Doubling time approx. 22 hr |
Cryopreservation: | 90%FBS/10% DMSO |
Mycoplasma Tested: | Yes |
Storage: | Liquid nitrogen |
Shipped: | Dry ice |
产品安全信息
Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, Newman RA, Cutter GR, Lindblad-Toh K, Kisseberth WC, Hunter LE, Subramanian S, Breen M, Modiano JF. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone. 2011 Sep;49(3):356-67. doi: 10.1016/j.bone.2011.05.008. Epub 2011 May 15. Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, Wilke VL, Charles JB, Munson S, Scott MC, Pozniak J, Carlson CS, Schaack J, Duke RC. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther. 2012 Dec;20(12):2234-43. doi: 10.1038/mt.2012.149. Epub 2012 Jul 31. Cannon CM, Pozniak J, Scott MC, Ito D, Gorden BH, Graef AJ, Modiano JF. Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors. Vet Comp Oncol. 2015 Mar;13(1):48-59. doi: 10.1111/vco.12018. Epub 2013 Feb 15.Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, KisseberthWC. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6. PubMed PMID:28109246; PubMed Central PMCID: PMC5251323.Scott MC, Tomiyasu H, Garbe JR, Cornax I, Amaya C, O'Sullivan MG, Subramanian S, Bryan BA, Modiano JF. Heterotypic mouse models of canine osteosarcomarecapitulate tumor heterogeneity and biological behavior. Dis Model Mech. 2016Dec 1;9(12):1435-1444. Epub 2016 Nov 3. PubMed PMID: 27874835; PubMed CentralPMCID: PMC5200896.Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF,Kisseberth WC, London CA. MiR-9 is overexpressed in spontaneous canineosteosarcoma and promotes a metastatic phenotype including invasion and migrationin osteoblasts and osteosarcoma cell lines. BMC Cancer. 2016 Oct 10;16(1):784.PubMed PMID: 27724924; PubMed Central PMCID: PMC5057229.Scott MC, Sarver AL, Tomiyasu H, Cornax I, Van Etten J, Varshney J, O'SullivanMG, Subramanian S, Modiano JF. Aberrant Retinoblastoma (RB)-E2F TranscriptionalRegulation Defines Molecular Phenotypes of Osteosarcoma. J Biol Chem. 2015 Nov20;290(47):28070-83. doi: 10.1074/jbc.M115.679696. Epub 2015 Sep 16. PubMed PMID:26378234; PubMed Central PMCID: PMC4653667.Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH. Interactionsbetween CXCR4 and CXCL12 promote cell migration and invasion of caninehemangiosarcoma. Vet Comp Oncol. 2017 Jun;15(2):315-327. doi: 10.1111/vco.12165. Epub 2015 Sep 3. PubMed PMID: 26337509.Lin W, Modiano JF, Ito D. Stage-specific embryonic antigen: determiningexpression in canine glioblastoma, melanoma, and mammary cancer cells. J Vet Sci.2017 Mar 30;18(1):101-104. doi: 10.4142/jvs.2017.18.1.101. PubMed PMID: 27456773;PubMed Central PMCID: PMC5366293.If you publish research with this product, please let us know so we can cite your paper.
主要内容
OSCA-32是一种犬骨肉瘤细胞系,其源自左侧手腕的肿瘤,在左侧手腕为9岁的飞行的女性大型比利牛斯.Highlights:在体外生长,在免疫缺陷小鼠基因表达谱中形成原位肿瘤异种移植物是一致的,与观察到的骨肉瘤源肉瘤的侵蚀性分子表型是侵袭性恶性肿瘤,其由基元转化的间充质转化细胞(以及因此肉瘤)产生,表现出骨细胞分化并产生恶性骨质。从Maime F. Modiano,VMD,Minnesota大学博士的实验室,双城市。
厂牌介绍
关于Kerafast Inc.
Kerafast 是一家位于波士顿的试剂公司,其主要使命是为QuanQiu科学界提供易于使用的独特实验室研究工具。我们的产品组合包括细胞系、抗体、小分子、染料等,其中许多在其他地方无法获得。自 2011 年成立以来,来自全球 190 多个机构的研究人员通过我们的在线平台提供了他们的创新试剂,无需通过传统的材料转让协议流程即可快速获取材料。
我们处理提供实验室的所有销售和运输物流,并从每次销售中返还丰厚的特许权使用费。因此,我们帮助提供实验室节省时间和资源,同时为进一步研究提供额外资金。采购科学家可以更轻松地发现和获取其他地方通常无法获得的独特试剂,同时还可以资助其他研究人员的工作。这创建了一个QuanQiu科学家社区,他们贡献和获取Reagent for the Greater Good,以加速他们自己的研究以及整体科学进步。
2018 年,Kerafast 与Absolute Antibody合并,后者是一家总部位于英国的公司,其愿景是为所有研究人员提供重组抗体技术。此次合并将两家公司聚集在一起,共同致力于改善科学界可用的研究工具的选择。
品牌标识
可能感兴趣的内容
2022-04-01
2024-05-19
2024-02-29
2022-03-31
2021-12-21
2022-04-01
2022-04-01
2022-04-01
2022-04-01
2022-04-01
2022-04-01
2019-05-08